Glucagon-Like Peptide-1(9-36) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Liberman, Ana ^a   Esser, Melanie ^a   Marx, Nikolaus ^a   Burgmaier, Mathias ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; COFILIN; CYCLIC AMP; F ACTIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INTERCELLULAR ADHESION MOLECULE 3; MYOSIN LIGHT CHAIN; PHOSPHATIDYLINOSITOL 3 KINASE; RANTES; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ARTICLE; ATHEROGENESIS; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE MIGRATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACTIN DEPOLYMERIZING FACTORS; ACTINS; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CELLS, CULTURED; CHEMOKINE CCL5; CHEMOKINE CXCL12; CHEMOTAXIS; CYCLIC AMP; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LYMPHOCYTE ACTIVATION; PEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TRANSPORT; RECEPTORS, GLUCAGON; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84874598730     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058445     Document Type: Article

References (19)

1. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, et al. (1996) Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39: 1546-1553.
2. Egan JM, Meneilly GS, Habener JF, Elahi D, (2002) Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87: 3768-3773.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M, (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234.
4. Drucker DJ, Nauck MA, (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
5. Burgmaier M, Heinrich C, Marx N (2012) Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes? Diabet Med.
6. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, et al. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 117: 2340-2350.
7. Nikolaidis LA, Elahi D, Shen YT, Shannon RP, (2005) Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-2408.
8. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
9. Marx N, Burgmaier M, Heinz P, Ostertag M, Hausauer A, et al. (2010) Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci 67: 3549-3555.
10. Knudsen LB, Pridal L, (1996) Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318: 429-435.
11. Wettergren A, Wojdemann M, Holst JJ, (1998) The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 19: 877-882.
12. Marx N, Burgmaier M, Heinz P, Ostertag M, Hausauer A, et al. (2010) Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci. 67: 3549-55.
13. Walcher D, Aleksic M, Jerg V, Hombach V, Zieske A, et al. (2004) C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. Diabetes 53: 1664-1670.
14. al-Aoukaty A, Rolstad B, Maghazachi AA, (1999) Recruitment of pleckstrin and phosphoinositide 3-kinase gamma into the cell membranes, and their association with G beta gamma after activation of NK cells with chemokines. J Immunol 162: 3249-3255.
15. Sanchez-Madrid F, del Pozo MA, (1999) Leukocyte polarization in cell migration and immune interactions. Embo J 18: 501-511.
16. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, et al. (1998) Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature 393: 805-809.
17. Serrador JM, Nieto M, Sanchez-Madrid F, (1999) Cytoskeletal rearrangement during migration and activation of T lymphocytes. Trends Cell Biol 9: 228-233.
18. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, et al. (2010) Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 151: 1520-1531.
19. Parker JC, Lavery KS, Irwin N, Green BD, Greer B, et al. (2006) Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. J Endocrinol 191: 93-100.